炎症性肠病中硫嘌呤诱导肝毒性的早期预测
本研究基于荷兰随机对照试验中首批270例启动硫嘌呤治疗的炎症性肠病患者,评估治疗1周时6-甲基巯基嘌呤核苷酸(6-MMPR)浓度对前20周肝毒性等不良反应的预测价值。47例(17%)出现肝毒性;在稳定剂量亚组(n=174)中,超过6-MMPR阈值3615 pmol/8×10^8红细胞者肝毒性风险升高(OR=3.8,95%CI 1.8-8.0),基于该阈值及年龄、男性、BMI构建的预测算法AUC=0.83(95%CI 0.75-0.91)。
要点
- 治疗1周6-MMPR超过3615 pmol/8×10^8红细胞与肝毒性风险升高相关(OR=3.8,95%CI 1.8-8.0)。
- 该阈值还与胃肠道不适(OR=2.4,95%CI 1.4-4.3)和全身不适(OR=2.0,95%CI 1.1-3.7)相关。
- 基于6-MMPR阈值及年龄、男性、BMI的预测算法AUC=0.83(95%CI 0.75-0.91)。
核心结论
- 在超过80%的患者中,硫嘌呤诱导的肝毒性可由治疗1周时升高的6-MMPR浓度及年龄、性别、BMI独立危险因素解释,从而允许对炎症性肠病进行个体化硫嘌呤治疗以预防早期失败。
研究设计与样本
- 队列研究纳入荷兰随机对照试验(评估治疗前硫嘌呤S-甲基转移酶基因型检测,ClinicalTrials.gov NCT00521950)中首批270例启动硫嘌呤治疗的炎症性肠病患者,于治疗1周时(T1)采集血样检测代谢物。
主要发现
- 47例患者(17%)在硫嘌呤治疗前20周内出现肝毒性。
- 定义T1 6-MMPR阈值为3615 pmol/8×10^8红细胞。
- 在稳定硫嘌呤剂量患者(n=174)中,超过6-MMPR阈值者肝毒性风险升高:OR=3.8(95%CI:1.8-8.0)。
- 年龄、男性性别和BMI为显著决定因素。
- 基于上述决定因素和6-MMPR阈值开发的肝毒性风险评估预测算法AUC=0.83(95%CI:0.75-0.91)。
关键数值与推荐
- 肝毒性定义为丙氨酸氨基转移酶升高超过正常上限2倍或丙氨酸氨基转移酶/碱性磷酸酶比值≥5。
- T1 6-MMPR阈值为3615 pmol/8×10^8红细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adverse reactions of azathioprine and mercaptopurine in IBD patients, often related to high steady-state 6-methylmercaptopurine ribonucleotide (6-MMPR) metabolite concentrations. AIM: To determine the predictive value of 6-MMPR concentrations 1 week after treatment initiation (T1) for the development of these adverse reactions, especially hepatotoxicity, during the first 20 weeks of treatment. METHODS: The cohort study consisted of the first 270 IBD patients starting thiopurine treatment as part of the Dutch randomised-controlled trial evaluating pre-treatment thiopurine S-methyltransferase genotype testing (ClinicalTrials.gov NCT00521950). Blood samples for metabolite assessment were collected at T1. Hepatotoxicity was defined by alanine aminotransaminase elevations >2 times the upper normal limit or a ratio of alanine aminotransaminase/alkaline phosphatase ≥5. RESULTS: Forty-seven patients (17%) presented hepatotoxicity during the first 20 weeks of thiopurine treatment. A T1 6-MMPR threshold of 3615 pmol/8 × 108 erythrocytes was defined. Analysis of patients on stable thiopurine dose (n = 174) showed that those exceeding the 6-MMPR threshold were at increased risk of hepatotoxicity: OR = 3.8 (95% CI: 1.8-8.0). Age, male gender and BMI were significant determinants. A predictive algorithm was developed based on these determinants and the 6-MMPR threshold to assess hepatotoxicity risk [AUC = 0.83 (95% CI: 0.75-0.91)]. 6-MMPR concentrations above the threshold also correlated with gastrointestinal complaints: OR = 2.4 (95% CI: 1.4-4.3), and general malaise: OR = 2.0 (95% CI: 1.1-3.7). CONCLUSIONS: In more than 80% of patients, thiopurine-induced hepatotoxicity could be explained by elevated T1 6-MMPR concentrations and the independent risk factors age, gender and BMI, allowing personalised thiopurine treatment in IBD to prevent early failure.
引用
- Wong DR, Coenen MJ, Derijks LJ, et al. Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. Aliment Pharmacol Ther. 2016. PMID: 27943397. doi:10.1111/apt.13879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。